In vitro, CaMKII controls cellular differentiation in AML differentiation [98] and cell proliferation in smooth muscle cells [127,128,129,130], lung cancer [111], medullary thyroid cancer [112], AML [98], glioma [120], T cell lymphoma [116], osteosarcoma [101], and colon [99], gastric [113] and prostate cancers [114]. Here, CAMK2G is linked to Familial prostate cancer.